Viewing Study NCT04951635


Ignite Creation Date: 2025-12-24 @ 10:13 PM
Ignite Modification Date: 2025-12-25 @ 7:48 PM
Study NCT ID: NCT04951635
Status: RECRUITING
Last Update Posted: 2022-06-16
First Post: 2021-06-30
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module